EBioMedicine: The importance of collaboration

Getting the balance right: Life Science vs Health Sciences

What do you get when you mix the editorial leadership from Cell with the editorial leadership of The Lancet, and sprinkle it with the publishing expertise of Elsevier?

The result is EBioMedicine, a gold open access translational research journal.

Getting the balance right: Life Science vs Health Sciences

The primary aim of EBioMedicine is to foster collaboration among life and health sciences. To that end, the scope of papers suitable for EBioMedicine is broad. Articles are relevant to audiences of both Cell Press and The Lancet journals; readerships that might not necessarily have overlapped. For example, basic findings from in vitro or animal models of disease are published alongside clinical research, health policy, and epidemiological studies.

This level of collaboration would be a challenge to nurture if we did not collaborate within publishing ourselves. My colleagues and I at EBioMedicine are physically embedded within the Cell Press and The Lancet offices and frequently confer with editors of these journals, benefiting from a wealth of expertise and editorial experience in order to help guide our decisions.

For papers that have been previously peer-reviewed at Cell Press or The Lancet, even faster review processes are possible because, in some cases, we are able to make a decision based on the prior reviews. Following peer review, we work directly with authors to negotiate an efficient action plan for manuscript revision. Using this workflow, re-review of revised manuscripts is expedited and a second round of revision is rare.

Translating science to improve health

This unique collaboration positions EBioMedicine as a hub for discourse among basic scientists, medical practitioners, health policymakers, and educators. Bidirectional communication and collaboration among scientists and clinicians is essential for advancing patient care and global health. Given the breadth of editorial expertise from Cell Press and The Lancet, EBioMedicine is uniquely poised to help facilitate these advances.

We at EBioMedicine care most about publishing good science that may ultimately help people, and we believe the collaboration and infrastructure behind us can helps us do just that.

Author biography

Ted DobieDr Frederick (Ted) Dobie is the US Scientific Editor of EBioMedicine. Prior to joining Elsevier in 2015, Ted was a postdoctoral fellow at the Broad Institute and Massachusetts Institute of Technology (USA) where he studied molecular, cellular, and neural circuit defects in the pathology of autism and schizophrenia. He was awarded his PhD in Neuroscience from the University of British Columbia (Canada) and holds a BSc in Biochemistry from the University of Victoria (Canada).

comments powered by Disqus